Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference
Acumen Pharmaceuticals (NASDAQ:ABOS) executives outlined key clinical and research milestones for the company's Alzheimer's disease pipeline during a discussion focused on its lead antibody, sabirnetug, and an enhanced brain delivery (EBD) collaboration with Japan-based JCR Pharmaceuticals.
Company...